NCT00253513 · OUTCOME

Number of Subjects Who Are Without Disease at One Year as Indicator of Disease Free Survival.

Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome · Source last updated 2012-06-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: One year

Groups in this outcome

Treosulfan and Fludarabine Conditioning

Conditioning with Treosulfan (12 or 14 g/m2, IV for 5 days) and Fludarabine (30 mg/m2, IV for 5 days) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treosulfan and Fludarabine Conditioning	60

Reported measurements

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treosulfan and Fludarabine Conditioning	58	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
58

denoms

counts
group Id
OG000
value
60
units
Participants

groups

description
Conditioning with Treosulfan (12 or 14 g/m2, IV for 5 days) and Fludarabine (30 mg/m2, IV for 5 days) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
id
OG000
title
Treosulfan and Fludarabine Conditioning

param Type

NUMBER

reporting Status

POSTED

time Frame

One year

title

Number of Subjects Who Are Without Disease at One Year as Indicator of Disease Free Survival.

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice